In a pilot study, South Carolina psychiatrist Michael Mithoefer is targeting PTSD with a controversial drug: methylenedioxymethamphetamine, or MDMA, commonly known as Ecstasy. He gave MDMA, along with psychotherapy, to 21 participants who had developed treatment-resistant PTSD as a result of experiences with crime or war. Only 15 percent of the MDMA-treated subjects continued to experience PTSD afterward, as opposed to 85 percent of the subjects who received psychotherapy with a placebo. Mithoefer considers the findings especially notable given that 20 of the 21 participants had previously failed to obtain relief from FDA-approved treatments. “The next step is to find out if this can be replicated elsewhere,” he says. The study, sponsored by the Multidisciplinary Association for Psychedelic Studies, was the first FDA-approved trial evaluating MDMA’s therapeutic applications. Additional clinical tests examining MDMA-based treatments for PTSD are under way in Switzerland and Israel.
Via Alexis Bright.